Abstract
Ulcerative colitis (UC) is an autoimmune chronic inflammatory bowel disease. Tumor necrosis factor-α-antagonist monoclonal antibodies are first-line biologicals used in adult patients with moderate-to-severe UC. However, infliximab is the only approved biological therapy for children with UC. With this understanding, golimumab might be another option for pediatric moderate-to-severe UC. This study aims to evaluate the efficacy and safety of golimumab in pediatric UC patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
